Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003))

Yanhong Jiang; Shuanghong Chen; Shenlin Hsiao; Haokun Zhang; Da Xie; Zi Jun Wang; Wendan Ren; Mingyao Liu; Jiaoyang Liao; Yuxuan Wu

doi:10.1016/j.ymthe.2024.11.031

Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003))

Yanhong Jiang, Shuanghong Chen, Shenlin Hsiao, Haokun Zhang, Da Xie, Zi Jun Wang, Wendan Ren, Mingyao Liu, Jiaoyang Liao, Yuxuan Wu

School of Life Sciences

Research output: Contribution to journal › Comment/debate

Abstract

(Molecular Therapy 33, 104–118; January 2025) In the originally published version of this article, there were errors in Figure 7E. The labeling of the PH1 group was incorrect. The label “PBS uninduced” was mistakenly spelled as “PBS induced,” and the PH1 group actually corresponds to the first three groups depicted in the figure. The authors apologize for any confusion.[Figure

Original language	English
Pages (from-to)	417-418
Number of pages	2
Journal	Molecular Therapy
Volume	33
Issue number	1
DOIs	https://doi.org/10.1016/j.ymthe.2024.11.031
State	Published - 8 Jan 2025

Access to Document

10.1016/j.ymthe.2024.11.031

Fingerprint

Dive into the research topics of 'Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003))'. Together they form a unique fingerprint.

Cite this

Jiang, Y., Chen, S., Hsiao, S., Zhang, H., Xie, D., Wang, Z. J., Ren, W., Liu, M., Liao, J., & Wu, Y. (2025). Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003)). Molecular Therapy, 33(1), 417-418. https://doi.org/10.1016/j.ymthe.2024.11.031

@article{2afb0f569ffa4b8fad93a3b9493b2b58,

title = "Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003))",

abstract = "(Molecular Therapy 33, 104–118; January 2025) In the originally published version of this article, there were errors in Figure 7E. The labeling of the PH1 group was incorrect. The label “PBS uninduced” was mistakenly spelled as “PBS induced,” and the PH1 group actually corresponds to the first three groups depicted in the figure. The authors apologize for any confusion.[Figure",

author = "Yanhong Jiang and Shuanghong Chen and Shenlin Hsiao and Haokun Zhang and Da Xie and Wang, \{Zi Jun\} and Wendan Ren and Mingyao Liu and Jiaoyang Liao and Yuxuan Wu",

note = "Publisher Copyright: {\textcopyright} 2024 The American Society of Gene and Cell Therapy",

year = "2025",

month = jan,

day = "8",

doi = "10.1016/j.ymthe.2024.11.031",

language = "英语",

volume = "33",

pages = "417--418",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Cell Press",

number = "1",

}

Jiang, Y, Chen, S, Hsiao, S, Zhang, H, Xie, D, Wang, ZJ, Ren, W, Liu, M, Liao, J & Wu, Y 2025, 'Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003))', Molecular Therapy, vol. 33, no. 1, pp. 417-418. https://doi.org/10.1016/j.ymthe.2024.11.031

Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003)). / Jiang, Yanhong; Chen, Shuanghong; Hsiao, Shenlin et al.
In: Molecular Therapy, Vol. 33, No. 1, 08.01.2025, p. 417-418.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum

T2 - Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003))

AU - Jiang, Yanhong

AU - Chen, Shuanghong

AU - Hsiao, Shenlin

AU - Zhang, Haokun

AU - Xie, Da

AU - Wang, Zi Jun

AU - Ren, Wendan

AU - Liu, Mingyao

AU - Liao, Jiaoyang

AU - Wu, Yuxuan

PY - 2025/1/8

Y1 - 2025/1/8

N2 - (Molecular Therapy 33, 104–118; January 2025) In the originally published version of this article, there were errors in Figure 7E. The labeling of the PH1 group was incorrect. The label “PBS uninduced” was mistakenly spelled as “PBS induced,” and the PH1 group actually corresponds to the first three groups depicted in the figure. The authors apologize for any confusion.[Figure

AB - (Molecular Therapy 33, 104–118; January 2025) In the originally published version of this article, there were errors in Figure 7E. The labeling of the PH1 group was incorrect. The label “PBS uninduced” was mistakenly spelled as “PBS induced,” and the PH1 group actually corresponds to the first three groups depicted in the figure. The authors apologize for any confusion.[Figure

UR - https://www.scopus.com/pages/publications/85210394874

U2 - 10.1016/j.ymthe.2024.11.031

DO - 10.1016/j.ymthe.2024.11.031

M3 - 评论/辩论

C2 - 39610245

AN - SCOPUS:85210394874

SN - 1525-0016

VL - 33

SP - 417

EP - 418

JO - Molecular Therapy

JF - Molecular Therapy

IS - 1

ER -

Erratum: Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption (Molecular Therapy (2025) 33(1) (104–118), (S1525001624006634), (10.1016/j.ymthe.2024.10.003))

Abstract

Access to Document

Other files and links

Fingerprint

Cite this